| Bioactivity | NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca2+ inward flow[1]. |
| Invitro | NP-313 (0-80 μM)可以以剂量依赖的方式抑制血小板的聚集。其中，对凝血酶和 A23187 诱导的血小板聚集，NP-313 的最大抑制程度可分别达到约 80% 和 60%[1]。 NP-313 (0-8 μM) 浓度依赖性地抑制 P-选择素表达以及胶原蛋白或者是凝血酶诱导的人血小板中血栓素 B 2 (TXB2) 生成。同时，NP-313 抑制 COX-1 和 TXA 2合酶的 IC 50 值分别为 1.5 和 3.9 µM[1]。 |
| In Vivo | NP-313 (i.v., 4-16 µg/g)在雄性 ICR 小鼠中显着延长了闭塞时间 (TTO)，延长了出血时间，抑制了由胶原蛋白 (10 µg/mL) 引起的血小板聚集[1]。 |
| Name | NP-313 |
| CAS | 5397-78-4 |
| Formula | C12H8ClNO3 |
| Molar Mass | 249.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Heng-Lan Kuo, et al. NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry. Br J Pharmacol. 2011 Apr;162(8):1871-83. |